18F-FDG PET/CT Prognostic Role in Diffuse Large B-cell Lymphoma Following Chemotherapy
10.13471/j.cnki.j.sun.yat-sen.univ（med.sci）.20230202.001
- VernacularTitle:18F-FDG PET/CT预测弥漫大B细胞淋巴瘤化疗后无进展生存期
- Author:
Shao-chun LIN
1
;
En-ting LI
2
;
Zhi-feng CHEN
3
;
Bing ZHANG
3
;
Zhou-lei LI
1
Author Information
1. Department of Radiology， The First Affiliated Hospital， Sun Yat-Sen University， Guangzhou 510080， China
2. School of Biomedical Engineering， Guangzhou Xinhua University， Guangzhou 510080， China
3. Department of Nuclear Medicine， The First Affiliated Hospital， Sun Yat-Sen University， Guangzhou 510080， China
- Publication Type:Journal Article
- Keywords:
diffuse large B-cell lymphoma（DLBCL）;
PET/CT;
therapeutic response;
predictive model
- From:
Journal of Sun Yat-sen University(Medical Sciences)
2023;44(2):262-270
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo assess the prognostic value of 18F-FDG PET/CT parameters for predicting therapeutic response in diffuse large B-cell lymphoma （DLBCL）. MethodsWe retrospectively analyzed the clinical data and 18F-FDG PET/CT radiomics features of 81 DLBCL patients enrolled between June 2015 and October 2020. Multivariate logistic regression analysis was used to identify the predictive factors for therapeutic response of DLBCL， based on which a predictive model was developed accordingly. The performance of the model was evaluated by receiver operating characteristic （ROC） curves and calibration plots. ResultsDuring the two years after first chemotherapy， 23 patients （28.3%） developed relapse and 58 patients （71.7%） had progression-free survival （PFS）. The analysis for the predictive capability of the binary logistic regression model incorporating the PET/CT features revealed that the imaging features of 18F-FDG PET/CT after chemotherapy were independent prognostic factors for PFS. Among them， SUVTHR-mean2 was the most important factor for predicting therapeutic response in DLBCL patients after chemotherapy， with a cutoff value of 2.00 （AUC=0.81）. Conclusions18F-FDG PET/CT showed a valuable prognostic performance for PFS in DLBCL patients after chemotherapy， with the imaging feature after chemotherapy SUVTLR-mean2 being the optimal independent predictor. Our predictive model of imaging features might have an important prognostic value in assessing the risk of disease progression， guiding the treatment and follow-up protocol， improving therapeutic efficiency and cutting down the medical cost.
